1:11 PM
 | 
Sep 12, 2017
 |  BC Extra  |  Clinical News

Aldeyra gains on Phase IIa data for dry eye candidate

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) jumped $1.40 (33%) to $5.65 on Tuesday after reporting that ADX-102 ophthalmic solution significantly improved multiple signs and symptoms of dry eye disease in a Phase IIa trial. Next half, the company plans to start a Phase IIb trial of ADX-102. The product is a topical eye...

Read the full 244 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >